NCT02785952 2025-05-21Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersSWOG Cancer Research NetworkPhase 3 Active not recruiting275 enrolled 15 charts